Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) Latest Company News

Oct 23, 2026, 10:35 UTC
Wolwo Bio-Pharmaceutical reported first-nine-month 2026 revenue of 910 million yuan, up 6.64% year over year, and net profit attributable to shareholders of 391 million yuan, up 13.46%.
Source:
- finance.sina.cn
Oct 23, 2026, 10:35 UTC
Wolwo Bio-Pharmaceutical reported third-quarter 2026 revenue of 396 million yuan, up 7.24% year over year, and net profit attributable to shareholders of 178 million yuan, up 5.94%.
Source:
- finance.sina.cn
Oct 20, 2026, 08:43 UTC
China approved Zhejiang Wolwo Bio-Pharmaceutical’s clinical trial application for S01D tablets, intended to treat drug-resistant pulmonary tuberculosis in adults.
Source:
- finance.sina.cn
Oct 11, 2026, 08:09 UTC
China's National Medical Products Administration approved a clinical-trial application for Zhejiang Wowu Stem Cell Technology's human umbilical cord mesenchymal stem cell type II injection for sepsis and/or septic shock.
Source:
- finance.sina.cn
Sep 8, 2026, 13:54 UTC
On September 8, 2026, Wolwo Bio-Pharmaceutical announced that due to divorce property division, its actual controller changed from Hu Gengxi and Yanni Chen to Yanni Chen alone, with Hu Gengxi's direct shares and his stake in Mingchen Investment transferred to family members.
Source:
- wap.eastmoney.com
- stock.jrj.com.cn
Sep 8, 2026, 13:54 UTC
On September 8, 2026, Hu Gengxi resigned as chairman, director, and legal representative of Wolwo Bio-Pharmaceutical, effective immediately, and will no longer hold any position in the company.
Source:
Sep 8, 2026, 11:05 UTC
On September 8, 2026, Hu Gengxi and YANNI CHEN dissolved their marriage and split property, resulting in Hu Gengxi holding 8.35% of Myhealth Biotechnology, becoming a single shareholder above 5%.
Source:
- finance.sina.cn
- m.21jingji.com
Sep 8, 2026, 11:05 UTC
Hu Gengxi resigned as chairman, director, and legal representative of Myhealth Biotechnology on September 8, 2026.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 27, 2026, 10:29 UTC
Wolwo Bio-Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders of 213 million yuan, up 20.59% year-on-year.
Source:
- finance.sina.cn
Aug 21, 2026, 09:10 UTC
China's National Medical Products Administration approved Wolwo Bio-Pharmaceutical's clinical trial application for its cat dander membrane agent, a Class 1 therapeutic biological product, for allergic rhinitis related to cat dander sensitization.
Source:
- finance.sina.cn

300357.SZ

Wolwo Bio-Pharmaceutical reported first-nine-month 2026 revenue of 910 million yuan, up 6.64% year over year, and net profit attributable to shareholders of 391 million yuan, up 13.46%.

Wolwo Bio-Pharmaceutical reported third-quarter 2026 revenue of 396 million yuan, up 7.24% year over year, and net profit attributable to shareholders of 178 million yuan, up 5.94%.

China approved Zhejiang Wolwo Bio-Pharmaceutical’s clinical trial application for S01D tablets, intended to treat drug-resistant pulmonary tuberculosis in adults.

China's National Medical Products Administration approved a clinical-trial application for Zhejiang Wowu Stem Cell Technology's human umbilical cord mesenchymal stem cell type II injection for sepsis and/or septic shock.

On September 8, 2026, Wolwo Bio-Pharmaceutical announced that due to divorce property division, its actual controller changed from Hu Gengxi and Yanni Chen to Yanni Chen alone, with Hu Gengxi's direct shares and his stake in Mingchen Investment transferred to family members.

On September 8, 2026, Hu Gengxi resigned as chairman, director, and legal representative of Wolwo Bio-Pharmaceutical, effective immediately, and will no longer hold any position in the company.

On September 8, 2026, Hu Gengxi and YANNI CHEN dissolved their marriage and split property, resulting in Hu Gengxi holding 8.35% of Myhealth Biotechnology, becoming a single shareholder above 5%.

Hu Gengxi resigned as chairman, director, and legal representative of Myhealth Biotechnology on September 8, 2026.

Wolwo Bio-Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders of 213 million yuan, up 20.59% year-on-year.

China's National Medical Products Administration approved Wolwo Bio-Pharmaceutical's clinical trial application for its cat dander membrane agent, a Class 1 therapeutic biological product, for allergic rhinitis related to cat dander sensitization.